Antibodies, Antinuclear

• 

  Subject Areas on Research

  • A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. 
  • A defect in the humoral immune response to protein antigens and haptens in immunoglobulin mu heavy-chain transgenic mice. 
  • A potentially abundant junctional RNA motif stabilized by m6A and Mg2. 
  • A role for immunogenic DNA in the pathogenesis of systemic lupus erythematosus. 
  • A simple enzyme-linked immunosorbent assay for antibodies to native DNA. 
  • A subgroup of murine monoclonal anti-deoxyribonucleic acid antibodies traverse the cytoplasm and enter the nucleus in a time-and temperature- dependent manner. 
  • ANA as an entry criterion for the classification of SLE. 
  • Altered T-dependent antigen responses and development of autoimmune symptoms in mice lacking E2A in T lymphocytes. 
  • An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. 
  • Anti-DNA and autoantibodies. 
  • Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. 
  • Anti-DNA antibodies in systemic lupus erythematosus. 
  • Anti-DNA antibodies in systemic lupus erythematosus: a case of mistaken identity? 
  • Anti-DNA antibodies--quintessential biomarkers of SLE. 
  • Anti-La antibodies. 
  • Anti-Ro and anti-nRNP response in unaffected family members of SLE patients. 
  • Antibodies against retroviral proteins and nuclear antigens in a subset of idiopathic CD4+ T lymphocytopenia patients. 
  • Antibodies to DNA. A perspective. 
  • Antibodies to DNA: infection or genetics? 
  • Anticardiolipin antibodies in unselected pregnant women. Relationship to fetal outcome. 
  • Anticentromere antibody. Clinical Correlations and association with favorable prognosis in patients with scleroderma variants. 
  • Antidouble stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements. 
  • Antinuclear antibodies and nuclear antigens in NZB myeloma ascitic fluids. 
  • Antinuclear antibodies and thyroid function in sexually abused girls. 
  • Antinuclear antibodies in healthy people: the tip of autoimmunity's iceberg? 
  • Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. 
  • Antinuclear antibody testing - misunderstood or misbegotten? 
  • Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE. 
  • Autoantibodies and their idiotypes. 
  • Autoantibodies and their significance. 
  • Autoantibodies before the clinical onset of systemic lupus erythematosus. 
  • Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. 
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. 
  • Autoimmunity: the nuclear arsenal of autoimmunity. 
  • B lymphocytes and systemic lupus erythematosus. 
  • Brief Report: HLA-DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis. 
  • Catastrophic antiphospholipid syndrome with concurrent thrombotic and hemorrhagic manifestations. 
  • Cellular requirements for anti-DNA production induced in mice by immunization with bacterial DNA. 
  • Characterization and comparison of commercially available antinuclear antibody kits using single pattern index sera. 
  • Characterization of monoclonal antibodies with specificity for DNA and the synthetic polypeptide antigen (T,G)-A-L. 
  • Clinical problem-solving. Taken out of context. 
  • Comparison of an enzyme immunoassay to an indirect fluorescent immunoassay for the detection of antinuclear antibodies. 
  • Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2. 
  • Curiouser and curiouser: the role(s) of AID expression in self-tolerance. 
  • DNA as a marker of cell death in systemic lupus erythematosus. 
  • Defects in mononuclear phagocytic system (MPS) function in autoimmune MRL-lpr/lpr mice. 
  • Deficient expression of antibodies specific for bacterial DNA by patients with systemic lupus erythematosus. 
  • Development of autoantibodies before the clinical onset of systemic lupus erythematosus. 
  • Differences in V kappa gene utilization and VH CDR3 sequence among anti-DNA from C3H-lpr mice and lupus mice with nephritis. 
  • Discrimination of antineutrophil antibodies from antinuclear antibodies using immunofluorescence on neutrophils and HL60 cells. 
  • Diverse endogenous light chains contribute to basement membrane reactivity in nonautoimmune mice transgenic for an anti-laminin Ig heavy chain. 
  • Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. 
  • Effect of sex on the induction of anti-DNA antibodies in normal mice immunized with bacterial DNA. 
  • Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. 
  • Exposure of mice to topical bovine thrombin induces systemic autoimmunity. 
  • Expression of a highly conserved anti-DNA idiotype in normal and autoimmune mice. 
  • Fatal lupus pleuritis presenting in pregnancy. A case report. 
  • Frequency of abnormal hand and wrist radiographs at time of diagnosis of polyarticular juvenile rheumatoid arthritis. 
  • Gamma delta T cell help of B cells is induced by repeated parasitic infection, in the absence of other T cells. 
  • Genetic control of inflammatory arthritis and glomerulonephritis in congenic lpr mice and their F1 hybrids. 
  • Genetic control of inflammatory arthritis in congenic lpr mice. 
  • Hybridoma SLE autoantibodies: insights for the pathogenesis of autoimmune disease. 
  • IgG binding of monoclonal anti-nuclear antibodies from MRL-lpr/lpr mice. 
  • Immune activation by bacterial DNA: a new genetic code. 
  • Immune phenotypes in individuals positive for antinuclear antibodies: The impact of race and ethnicity. 
  • Immune recognition of DNA in SLE. 
  • Immune response to DNA in systemic lupus erythematosus. 
  • Immune responses to DNA in normal and aberrant immunity. 
  • Immunization with the Sm nuclear antigen induces anti-Sm antibodies in normal and MRL mice. 
  • Immunochemical properties of anti-DNA antibodies in the sera of patients with Escherichia coli bacteremia. 
  • Immunological properties of bacterial DNA. 
  • In vitro and in vivo expression of a nephritogenic Ig heavy chain determinant: pathogenic autoreactivity requires permissive light chains. 
  • In vitro autoantibody production by normal adult and cord blood B cells. 
  • Independent expression of autoantibodies in systemic lupus erythematosus. 
  • Independently derived murine glomerular immune deposit-forming anti-DNA antibodies are encoded by near-identical VH gene sequences. 
  • Induction of anti-double stranded DNA antibodies in normal mice by immunization with bacterial DNA. 
  • Induction of immune-mediated glomerulonephritis in normal mice immunized with bacterial DNA. 
  • Inhibition of in vitro NZB antibody responses by cyclosporine. 
  • Liposarcoma presenting as an intraluminal ureteral mass. 
  • Lupus-like nephrotropic autoantibodies in non-autoimmune mice harboring an anti-basement membrane/anti-DNA Ig heavy chain transgene. 
  • Lymphocytic lymphoma and systemic lupus erythematosus: their coexistence with antibody to the Sm antigen. 
  • Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. 
  • Mechanisms of anti-DNA antibody expression in normal and aberrant immunity. 
  • Mechanisms of antinuclear antibody production in the rheumatic diseases. 
  • Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. 
  • Microparticles as a source of extracellular DNA. 
  • Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. 
  • Microparticles as autoadjuvants in the pathogenesis of SLE. 
  • Molecular analysis of spontaneous nephrotropic anti-laminin antibodies in an autoimmune MRL-lpr/lpr mouse. 
  • Molecular and structural analysis of nuclear localizing anti-DNA lupus antibodies. 
  • Molecular characterization of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. Differences from spontaneous anti-DNA in the content and location of VH CDR3 arginines. 
  • Molecular properties of anti-DNA induced in preautoimmune NZB/W mice by immunization with bacterial DNA. 
  • Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. 
  • Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. 
  • Neuroendocrine response to cold in Raynaud's syndrome. 
  • New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. 
  • New insights into the role of antinuclear antibodies in systemic lupus erythematosus. 
  • Ophthalmologic examinations in children with juvenile rheumatoid arthritis. 
  • Patterns of autoantibody expression in pediatric and adult systemic lupus erythematosus. 
  • Polyspecific binding of Escherichia coli beta-galactosidase by murine antibodies to DNA. 
  • Practice-based differences in paediatric discoid lupus erythematosus. 
  • Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma. 
  • Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. 
  • Prognostic marker analysis in pediatric intracranial ependymomas. 
  • Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. 
  • Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity. 
  • Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al. 
  • Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al. 
  • Response to: 'ANA testing in "real life"' by Infantino etal. 
  • Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al. 
  • Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro. 
  • Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler. 
  • Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al. 
  • Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al. 
  • Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al. 
  • Role of Antinuclear Antibody Determinations in Classification Criteria for Systemic Lupus Erythematosus: Comment on the Article by Leuchten et al. 
  • Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. 
  • Scavenging nucleic acid debris to combat autoimmunity and infectious disease. 
  • Selective recognition of DNA antigenic determinants by murine monoclonal anti-DNA antibodies. 
  • Serum immunoglobulin levels in systemic lupus erythematosus: the effects of age, sex, race and disease duration. 
  • Specificity analysis of monoclonal anti-DNA antibodies. 
  • Specificity and idiotypic analysis of a monoclonal anti-Sm antibody with anti-DNA activity. 
  • Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. 
  • Specificity and immunochemical properties of antibodies to bacterial DNA. 
  • Specificity of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. 
  • Specificity of autoantibodies for recombinant 60-kd and 52-kd Ro autoantigens. 
  • Spontaneous expression of antibodies to DNA of various species origin in sera of normal subjects and patients with systemic lupus erythematosus. 
  • Standardization of anti-DNA antibody assays. 
  • Structural features of nephritogenic lupus autoantibodies. 
  • Structural properties of a subset of nephritogenic anti-DNA antibodies. 
  • Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid. 
  • Systemic lupus erythematosus and related diseases. 
  • Systemic lupus erythematosus. 
  • Systemic lupus erythematosus. Diagnosis and treatment. 
  • Temporal correlation of antibody responses to different epitopes of the human La autoantigen. 
  • The B-cell repertoire for autoantibodies: frequency of precursor cells for anti-DNA antibodies. 
  • The Role of Cell Death in the Pathogenesis of SLE: Is Pyroptosis the Missing Link? 
  • The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA. 
  • The anti-La response of a single MRL/Mp-lpr/lpr mouse: specificity for DNA and VH gene usage. 
  • The antibody response of normal mice to immunization with single-stranded DNA of various species origin. 
  • The antigenic properties of bacterial DNA in normal and aberrant immunity. 
  • The binding of SLE autoantibodies to mitochondria. 
  • The binding of anti-DNA antibodies to phosphorothioate oligonucleotides in a solid phase immunoassay. 
  • The complex role of DNA, histones and HMGB1 in the pathogenesis of SLE. 
  • The effect of polyamines on the binding of anti-DNA antibodies from patients with SLE and normal human subjects. 
  • The fine specificity of monoclonal anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. 
  • The immunologic properties of DNA. 
  • The influence of DNA size on the binding of anti-DNA antibodies in the solid and fluid phase. 
  • The influence of DNA size on the binding of antibodies to DNA in the sera of normal human subjects and patients with systemic lupus erythematosus (SLE). 
  • The influence of Yaa on anti-DNA responses of B6-lpr mice. 
  • The influence of the lpr gene on B cell activation: differential antibody expression in lpr congenic mouse strains. 
  • The influence of variable-region somatic mutations on the specificity and pathogenicity of murine monoclonal anti-DNA antibodies. 
  • The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers. 
  • The mechanism of autoantibody production in an autoimmune MRL/lpr mouse. 
  • The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. 
  • The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus. 
  • The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus. 
  • The role of bacterial DNA in autoantibody induction. 
  • The role of cpg sequences in the induction of anti-DNA antibodies. 
  • The role of extracellular DNA in autoimmunity in SLE. 
  • The role of innate immunity in the induction of autoimmunity. 
  • The role of microparticles in the generation of immune complexes in murine lupus. 
  • The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen. 
  • The use of fluorometric assays to assess the immune response to DNA in murine systemic lupus erythematosus. 
  • Thromboxane receptor blockade reduces renal injury in murine lupus nephritis. 
  • Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. 
  • VH gene analysis of spontaneously activated B cells in adult MRL-lpr/lpr mice. J558 bias is not limited to classic lupus autoantibodies. 
  • Variability in Antinuclear Antibody Testing to Assess Patient Eligibility for Clinical Trials of Novel Treatments for Systemic Lupus Erythematosus. 
• 

  Keywords of People

  • Schanberg, Laura Eve, Professor of Pediatrics, Pediatrics, Rheumatology